non-pain indication and is intended to demonstrate the potential
utility of tezampanel for indications beyond migraine and chronic
-- Complete the ongoing Phase I maximum tolerated dose trial of
NGX426, the oral prodrug of tezampanel, in the first half of the
-- Initiate a Phase I single-dose trial of NGX426 in a capsaicin model
for neuropathic pain in the first half of the year. The purpose of
this trial is to show that tezampanel may be an effective analgesic
when administered orally as NGX426. Tezampanel has been shown in
six Phase II trials to be an effective analgesic when administered
-- Initiate a Phase I multiple dose trial of NGX426 in the second half
of the year.
-- Initiate a Phase II trial of NGX267 in xerostomia, or dry mouth,
secondary to Sjogren's syndrome in the first half of the year. The
company has demonstrated the safety of single and multiple doses of
NGX267 in three Phase I trials involving healthy volunteers. In two
of these studies, statistically significant increases in salivary
flow were demonstrated.
Expand Business Development Initiatives Across Pipeline
The company will evaluate partnership opportunities for tezampanel and NGX426 as treatments for migraine headache and other chronic pain and non-pain indications. This will be in addition to the company's current partnering activities involving its gamma-secretase modulator (GSM) program, phenserine, Posiphen(TM) and bisnorcymserine.
With the more focused development and discovery activities and the
February 28, 2008, conclusion of the discovery-phase GSM collaboration with
Eisai Co., Ltd., the compan
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved